Quintiles Transnational Holdings Aktie [WKN DE: A1T788 / ISIN: US74876Y1010]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Quintiles Transnational Holdings INC

17.02.21		IQVIA Announces Pricing of Offering of Senior Notes (Businesswire)
16.02.21		IQVIA Announces Offering of Senior Notes (Businesswire)
11.02.21		IQVIA’s Orchestrated Customer Engagement (OCE) Solution Selected by 140 Life Sciences Companies in Nearly 90 Countries (Businesswire)
10.02.21		IQVIA Reports Fourth-Quarter and Full-Year 2020 Results Raises Full-Year 2021 Guidance (Businesswire)
04.02.21		IQVIA Recognized as Leading eCOA/ePRO Provider in Latest 2020 ISR eCOA/ePRO Market Report (Businesswire)
01.02.21		IQVIA Named to FORTUNE’s 2021 List of "World’s Most Admired Companies” (Businesswire)
26.01.21		IQVIA to Announce Fourth-Quarter and Full-Year 2020 Results on February 10, 2021 (Businesswire)
05.01.21		Laboratoires Théa Selects IQVIA OCE and OneKey to Accelerate Its Global Digital Transformation (Businesswire)
21.12.20		Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ® Assay, the Leading Quantitative Large-Scale Immunosequencing Solution (Businesswire)
17.12.20		Prescription Opioid Use in the U.S. has Declined by 60% from 2011 Peak, According to New Report from the IQVIA™ Institute for Human Data Science (Businesswire)
16.12.20		IQVIA and Servier Collaborate to Reinvent Clinical Development (Businesswire)
07.12.20		IQVIA Supports Collaborative Forum of Top Pharma Leaders to Advance the Use and Acceptance of Real World Evidence (Businesswire)
02.11.20		IQVIA’s Orchestrated Customer Engagement Platform Selected by Zentiva to Accelerate Digital Capabilities (Businesswire)
20.10.20		IQVIA Reports Third-Quarter 2020 Results, Raises Full-Year 2020 Guidance and Provides 2021 Outlook (Businesswire)
12.10.20		IQVIA Joins FDA to Advance COVID-19 Understanding at Community Level through COVID Active Research Experience (CARE) Project (Businesswire)
07.10.20		IQVIA to Announce Third-Quarter Results on October 20, 2020 (Businesswire)
06.10.20		IQVIA Institute for Human Data Science Study: Biosimilars Reach Inflection Point – On Track to Reduce Drug Costs by $100 Bn Over Next Five Years (Businesswire)
14.09.20		IQVIA’s eCOA Solution Receives 2020 Fierce Innovation Award (Businesswire)
31.08.20		IQVIA’s RIM Smart Honored as Gold Stevie® Award Winner in 2020 American Business Awards® (Businesswire)
05.08.20		IQVIA’s Nancy Dreyer and Deepa Desai Honored with 2020 PharmaVOICE Awards (Businesswire)
04.08.20		Drug Prices Have Become More Affordable to Most Patients, says U.S. Medicine Spending Study from the IQVIA Institute for Human Data Science (Businesswire)
29.07.20		IQVIA Launches OCE Optimizer to Help Intelligently Plan HCP Engagements and Maximize Commercial Effectiveness (Businesswire)
23.07.20		IQVIA Human Data Science Research Collaborative Initiative Waives Data Access Fees for Academic Researchers (Businesswire)
22.07.20		IQVIA Reports Second-Quarter 2020 Results and Raises Full-Year 2020 Guidance (Businesswire)
22.07.20		IQVIA Appoints Ron Bruehlman Executive Vice President and interim Chief Financial Officer (Businesswire)
20.07.20		IQVIA and JDRF Collaborate to Improve Understanding of Type 1 Diabetes Using Real World Data (Businesswire)
14.07.20		IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine (Businesswire)
08.07.20		IQVIA to Announce Second-Quarter Results on July 22, 2020 (Businesswire)
02.07.20		IQVIA Collaborates with LMC Manna Research to Launch the Largest Clinical Investigation Site in Canada (Businesswire)
03.06.20		Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Improves Oncology’s Standard of Care with Genomics Technology Collaboration (Businesswire)
21.05.20		IQVIA Launches the First Solution to Address the Unique Business and Compliance Needs of Healthcare Professionals as Part of Its OCE Suite (Businesswire)
20.05.20		IQVIA Collaborates with Australian Medical Research Institute on COVID-19 Study to Support Frontline Healthcare Workers (Businesswire)
29.04.20		IQVIA Joins UK Government Collaboration to Provide Single Research Platform to Speed Development of New COVID-19 Treatments (Businesswire)
28.04.20		IQVIA Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance and Updates Full-Year 2020 Guidance (Businesswire)
07.04.20		IQVIA Launches Broad, Open COVID-19 Registry Platform to Advance Understanding, Collaboration, and Research (Businesswire)
07.04.20		IQVIA Launches First Technology-Enabled COVID-19 Trial Matching Solution within the U.S. to Accelerate Treatment and Vaccine Development (Businesswire)
24.03.20		Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Collaborates with University of Texas Medical Branch to Help Accelerate Development of COVID-19 Vaccines (Businesswire)
20.02.20		IQVIA Launches Avacare Clinical Research Network to Increase Patients’ Clinical and Research Options (Businesswire)
13.02.20		IQVIA Announces Repurchase of Common Stock (Businesswire)
03.02.20		IQVIA Launches FluSTAR Mobile App to Help Consumers Manage Their Health During Flu and Cold Season (Businesswire)
30.01.20		IQVIA’s Breakthrough Natural Language Processing Platform Receives 2019 Fierce Innovation Award (Businesswire)
29.01.20		IQVIA to Announce Fourth-Quarter and Full-Year 2019 Results and Issue 2020 Guidance on February 12, 2020 (Businesswire)
23.01.20		AP-HP, Europe’s Leading Clinical Research Center, and IQVIA Collaborate to Launch the Largest Clinical Investigation Site in Europe (Businesswire)
21.01.20		IQVIA Named to FORTUNE’s 2020 List of "World’s Most Admired Companies” (Businesswire)
19.12.19		AstraZeneca Selects IQVIA OCE to Help Further its Digital Focus (Businesswire)
30.10.19		IQVIA Reports Third-Quarter 2019 Results (Businesswire)
16.10.19		IQVIA to Announce Third-Quarter 2019 Results on October 30, 2019 (Businesswire)
02.10.19		IQVIA Launches Orchestrated Patient Engagement (Businesswire)
01.10.19		IQVIA Launches IQVIA Consumer Health to Meet the Growing Business Needs of the Retail Health Sector (Businesswire)
18.09.19		IQVIA Collaborates with Cancer Researchers to Advance Use of Real World Evidence (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Erste Group-Aktie stürzt dennoch ab: Erste Group macht mehr Gewinn

Palantir-Aktie mit stärkerem Wertzuwachs als NVIDIA-Aktie - Darum schlagen Experten jetzt Alarm

Ripple Kurs Prognose: Ist der Boden erreicht und folgt jetzt ein neuer Bullrun?

Tesla-Aktie: Rückgang der Auslieferungen deutet auf Herausforderungen hin

Pierer Mobility-Aktie deutlich stärker: KTM-Insolvenz - BMW schließt Einstieg wohl aus

Diese Aktien empfehlen Experten zu kaufen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	03.03.2025 23:57
Kaufwert:	EUR
	Hinzufügen Speichern